Sign In
Buy DSRLF
$71.66
+0 (+0%)
At Close: Nov 17, 2025
Invesco International Small-Mid Company Fund Q3 2025 Portfolio Positioning
03:56am, Wednesday, 05'th Nov 2025
Invesco International Small-Mid Company Fund added six new positions and exited 11 positions during the quarter. We are benchmark independent, bottom-up investors, focusing on company fundamentals rat
DiaSorin: Anticipate A Double-Digit EBITDA Growth Rate
10:30am, Friday, 02'nd May 2025
DiaSorin's 2024 revenue grew by 3%, with an underlying increase of 7%, and net profit rose to 188.1M EUR, reflecting a 17% EPS increase. The company generated strong free cash flow of 191M EUR, enabli
DiaSorin S.p.A. (DSRLF) Q4 2024 Earnings Call Transcript
05:16pm, Friday, 14'th Mar 2025
DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2024 Results Conference Call March 14, 2025 12:30 PM ET Company Participants Carlo Rosa - CEO Piergiorgio Pedron - CFO Conference Call Participants Kavya Deshpande - U
Italy's DiaSorin ex-Covid revenue in line with guidance
12:31pm, Friday, 14'th Mar 2025
Italian medical diagnostics group DiaSorin on Friday reported a 3% rise in 2024 revenue, citing dampened demand for its products with a milder Flu season compared to the previous year.
DiaSorin S.p.A. (DSRLF) Q2 2024 Earnings Call Transcript
06:41pm, Monday, 29'th Jul 2024
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2024 Earnings Conference Call July 29, 2024 11:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
07:25pm, Friday, 15'th Mar 2024
DiaSorin S.p.A. (DSRLF) Q4 2023 Earnings Call Transcript
Diasorin 2023 revenue drops 14%, in line with guidance; shares fall
10:01am, Friday, 15'th Mar 2024
Italian medical diagnostic group Diasorin on Friday reported a double-digit drop in revenue for 2023, in line with its revenue guidance for the year, but shares dropped as much as 7.3%.
New Strong Sell Stocks for January 29th
04:26am, Monday, 29'th Jan 2024
T, DSRLF and HAFC have been added to the Zacks Rank #5 (Strong Sell) List on January 29, 2023.
DiaSorin S.p.A. (DSRLF) Q3 2023 Earnings Call Transcript
03:28pm, Friday, 03'rd Nov 2023
DiaSorin S.p.A. (OTCPK:DSRLF) Q3 2023 Earnings Conference Call November 3, 2023 11:30 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Confe
DiaSorin S.p.A. (DSRLF) Q2 2023 Earnings Call Transcript
10:01am, Saturday, 29'th Jul 2023
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2023 Earnings Conference Call July 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferenc
DiaSorin S.p.A. (DSRLF) Q4 2022 Earnings Call Transcript
01:58pm, Monday, 27'th Mar 2023
DiaSorin S.p.A. (OTCPK:DSRLF) Q4 2022 Earnings Conference Call March 27, 2023 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen
DiaSorin: Overvalued Italian Healthcare Company
02:53pm, Thursday, 02'nd Mar 2023
DiaSorin S.p.A. is an Italian healthcare company that develops, produces, and sells reagent kits and analyzer instruments mostly used to detect patients' diseases. DiaSorin benefited from the outbreak
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q2 2022 Results - Earnings Call Transcript
04:34am, Monday, 08'th Aug 2022
DiaSorin S.p.A. (OTCPK:DSRLF) Q2 2022 Earnings Conference Call August 3, 2022 9:00 AM ET Company Participants Carlo Rosa - Chief Executive Officer Piergiorgio Pedron - Chief Financial Officer Conferen
DiaSorin's (DSRLF) CEO Carlo Rosa on Q1 2022 Results - Earnings Call Transcript
04:50pm, Saturday, 07'th May 2022
DiaSorin S.p.A. (OTCPK:DSRLF) Q1 2022 Earnings Conference Call May 6, 2022 11:30 AM ET Company Participants Carlo Rosa – Chief Executive Officer Piergiorgio Pedron – Chief Financial Officer Confer
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript
05:12pm, Wednesday, 16'th Mar 2022
DiaSorin S.p.A. (DSRLF) CEO Carlo Rosa on Q4 2021 Results - Earnings Call Transcript
